Back to EZorb Newsletter Index

In this issue:

1. Share Success: Letters From Readers
2. Research News: Importance of 2nd COVID-19 Vaccine Dose for RA Patients
3. Useful Links
4. What Are Others Saying About EZorb and Marvlix?

Letter I: From James P.
Received at Testimonial Submit Form Sunday, March 28, 2021 at 19:23:17
(Unedited)

Hi, my name is James P. I have been taking EZorb for over 3 years.

Prior to date I had weekly Doctor office calls for over 40 years. The last 2 years I had only one office call. This is unheard of in medical science.

I am 83 years old and a full time farmer. In fact my neighbor on another farm I own just had her 105th birthday. What a great life I have and all because of Ezorb.

Just think. I might be one in 50,000 farmers. What about the other 49,999 farmers.

Thank you,

James P.

Letter II: From Christine S.
Received at Testimonial Submit Form Monday, May 31, 2021 at 13:44:09
(Unedited)

Hi, my name is Christine S. I have been suffering with a bone spur on the bottom of my foot for two years.

I did a lot of internet research and decided most traditional treatments would be not very helpful. After finding EZorb on line I decided to try it.

I stopped after about two months with some improvement. Stopping was dumb as my foot deteriorated again. I decided to really try EZorb properly again.

After three months the improvement in my foot is remarkable. I believe it is at least 80% better. If I have that much improvement in my foot, the rest of me must be benefiting as well.

As a 75 year old, clearly my calcium intake and utilization is important so I will be taking it consistently from now on. Thanks for a great product!

Our newsletter reaches over 200,000 subscribers worldwide. Success stories you shared in the past have made a great impact on many people's life.

Please email your story to sharesuccess @ ezorbonline.com or simply post it to Testimonial Submit Form. Your personal information will never be revealed to the public.

Rheumatoid arthritis (RA) patients are more likely than healthy controls to require both doses of vaccines against SARS-CoV-2 in order to mount an adequate immune response, researchers report.

As outlined in a comment published in The Lancet Rheumatology, 53 RA patients receiving continuous DMARD treatment had significantly lower median titers of antibodies against the SARS-CoV-2 spike protein than 20 healthy controls at 3 weeks after the first dose (0.4 vs 99.2 U/mL) and 2 weeks after the second dose (657 vs 2500 U/mL) of the Pfizer-BioNTech (BNT162b2) or Moderna (mRNA-1273) vaccine.

When a titer of more than 15 U/mL was applied as the cutoff for an adequate response, just 10% of RA patients met this threshold after the first dose, compared with 90% of controls, a significant difference. This difference remained significant when a more stringent cutoff was used, with 2% of RA patients and 45% of controls having titers higher than 133 U/mL after the first dose.

After the second dose, 88% of RA patients had antibody titers higher than 15 U/mL and 82% had titers above 133 U/mL, while all individuals in the control group had titers above the higher cutoff.

“These data suggest that the kinetics of the vaccine-induced humoral immune response differs between patients with rheumatoid arthritis who are taking DMARDs and healthy individuals,” and highlight “the importance of a second vaccination” in RA patients, conclude Andrea Rubbert-Roth (Kantonsspital St Gallen, Switzerland) and colleagues.

Original research was published in Lancet Rheumatol 2021; doi: 10.1016/ S2665-9913(21)00186-7.

EZorb - Frequently Asked Questions & Answers

EZorb Clinical Studies

Marvlix Benefits

Order Now

EZorb and Marvlix have restored confidence in thousands of men and women. It has brought happiness and healthy life to families around the world. Click here to read what people say about EZorb and Marvlix.

Back to EZorb Newsletter Index